Interleukin-2 Pipeline Assessment Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight

DelveInsight's, "Interleukin-2 (IL-2) Inhibitor Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10 pipeline drugs in Interleukin-2 (IL-2) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Get a Detailed Overview of the Interleukin-2 Inhibitor Clinical Trial Activities and Regulatory Developments in the domain @ https://www.delveinsight.com/sample-request/interleukin-2-il-2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Interleukin-2 Pipeline Report
• On 08 October 2025, M.D. Anderson Cancer Center announced a study for primary objective will be to determine whether patients receiving the combination of dendritic cells and high dose IL-2 (Cohort A) have sustained persistence of infused T cells compared to patients treated with T cells and high dose IL-2 alone.
• DelveInsight's Interleukin-2 pipeline report depicts a robust space with 8i+ active players working to develop 10+ pipeline therapies for Interleukin-2 treatment.
• The leading Interleukin-2 Companies such as Sanofi, Medicenna Therapeutics, Bioniz Therapeutics, Celerion, Asher Biotherapeutics, Xilio Therapeutics, Aulos Bioscience, Krystal Biotech, Werewolf Therapeutics, Xencor, Shanghai Junshi Biosciences, Egle Therapeutics, ILTOO Pharma.
• Promising Interleukin-2 Pipeline Therapies such as ALT-801, Gemcitabine, Cisplatin, Ipilimumab, Feladilimab, Docetaxel, Rozibafusp Alfa and others.

Discover how the Interleukin-2 treatment paradigm is evolving. Access DelveInsight's in-depth Interleukin-2 Pipeline Analysis for a closer look at promising breakthroughs @ Interleukin-2 Clinical Trials and Studies- https://www.delveinsight.com/sample-request/interleukin-2-il-2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interleukin-2 Emerging Drugs Profile

• Aldesleukin: ILTOO Pharma
Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells. Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. The drug is in clinical trial Phase II stage.

• XmAb564: Xencor
XmAb564 is a wholly owned, monovalent IL-2-Fc fusion protein, engineered to selectively activate and expand Tregs for the potential treatment of patients with autoimmune diseases. XmAb564 is engineered with reduced binding affinity for IL-2's beta receptor (IL-2Rß, CD122) and increased binding affinity for its alpha receptor (IL-2Ra, CD25). Xencor is conducting a randomized, double-blind, placebo-controlled, multiple-ascending dose Phase 1b clinical study to evaluate the safety and tolerability of XmAb564, administered subcutaneously in patients with atopic dermatitis and psoriasis. The drug is in Phase I stage of its clinical trial.

The Interleukin-2 Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Interleukin-2 with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interleukin-2 Treatment.
• Interleukin-2 Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interleukin-2 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interleukin-2 market

Explore groundbreaking therapies and clinical trials in the Interleukin-2 Pipeline. Access DelveInsight's detailed report now! @ New Interleukin-2 Drugs- https://www.delveinsight.com/sample-request/interleukin-2-il-2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interleukin-2 Companies
Sanofi, Medicenna Therapeutics, Bioniz Therapeutics, Celerion, Asher Biotherapeutics, Xilio Therapeutics, Aulos Bioscience, Krystal Biotech, Werewolf Therapeutics, Xencor, Shanghai Junshi Biosciences, Egle Therapeutics, ILTOO Pharma.

Interleukin-2 (IL-2) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Interleukin-2 Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Interleukin-2 Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/interleukin-2-il-2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Interleukin-2 Pipeline Report
• Coverage- Global
• Interleukin-2 Companies- Sanofi, Medicenna Therapeutics, Bioniz Therapeutics, Celerion, Asher Biotherapeutics, Xilio Therapeutics, Aulos Bioscience, Krystal Biotech, Werewolf Therapeutics, Xencor, Shanghai Junshi Biosciences, Egle Therapeutics, ILTOO Pharma.
• Interleukin-2 Pipeline Therapies such as ALT-801, Gemcitabine, Cisplatin, Ipilimumab, Feladilimab, Docetaxel, Rozibafusp Alfa and others.
• Interleukin-2 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Interleukin-2 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Interleukin-2 drug development? Find out in DelveInsight's exclusive Interleukin-2 Pipeline Report-access it now! @ Interleukin-2 Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/interleukin-2-il-2-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Interleukin-2 (IL-2) Inhibitor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Interleukin-2 (IL-2) Inhibitor - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Aldesleukin: ILTOO Pharma
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. THOR-707: Sanofi
15. Mid Stage Products (Phase II)
16. Preclinical Stage Products
17. EGL-001: Egle Therapeutics
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Interleukin-2 (IL-2) Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding
21. Interleukin-2 (IL-2) Inhibitor - Unmet Needs
22. Interleukin-2 (IL-2) Inhibitor - Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.